Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: Analysis of the FDA summary basis of approval reports

Annals of Clinical Psychiatry

Volumn 19, Issue 1, 2007, Pages 31-36

  Khan, Arif ^a,b,c   Schwartz, Kelly ^a  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Antidepressants; Clinical drug studies; Depression; Suicide; Symptom reduction

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; PAROXETINE; PLACEBO;

CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUICIDE; SUICIDE ATTEMPT;

ANALYSIS OF VARIANCE; CITALOPRAM; DRUG APPROVAL; FLUOXETINE; HUMANS; PAROXETINE; PERSONALITY INVENTORY; PLACEBO EFFECT; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SUICIDE; SUICIDE, ATTEMPTED; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33947322372     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230601163550     Document Type: Review

References (20)

1. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B: Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomized controlled trials. BMJ 2005; 330:396
2. Gunnell D, Saperia J, Ashby D: Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 2005; 330:385
3. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ: Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry 2005; 65:1456-1462
4. Gibbons RD, Hur K, Bhaumik DK, Mann JJ: The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62:165-172
5. Jick H, Kaye JA, Lick SS: Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292:338-343
6. Khan A, Warner HA, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57:311-317
7. Khan A, Khan SR, Leventhal RM, Brown WA: Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analyses of the Food and Drug Administration database. Int J Neuropsychopharmacol 2001; 4:113-118
8. Rotham KJ, Michels KB: The continuing unethical use of placebo controls. N Engl J Med 1995; 332:60-62
9. Greenberg RP, Bornstein RF, Zboroorowski MG, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182:547-551
10. Emanuel EZ, Miller FG: The ethics of placebo-controlled trials - A middle ground. N Engl J Med 2001; 435:915-919
11. Lavori PW: Placebo control groups in randomized treatment trails: A statistician's perspective. Biol Psychiatry 2000; 47:717-723
12. Leber P: The use of placebo control groups in the assessment of psychiatric drugs: An historical context. Biol Psychiatry 2000; 47:699-706
13. Miller FG: Placebo-controlled trials in psychiatric research: An ethical perspective. Biol Psychiatry 2000; 47:707-716
14. U.S. Congress (1999) Freedom of Information Act. 5 Congress 552 (1994 and Supplement II 1996) (http://www.usdij.gov/04foia/)
15. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:55-62
16. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
17. Khan A, Khan S, Leventhal R, Krishnan R, Gorman J: An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics. Biol Psychiatry 2002; 52:62-67
18. Khan A, Leventhal RM, Khan SR, Brown WA: Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22:40-45
19. Khan A, Brodhead AE, Kolts RL, Brown WA: Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39:145-150
20. Frank JD, Frank JB: Persuasion and Healing: A comparative study of psychotherapy. Baltimore, MD: The Johns Hopkins University Press; 1991